These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1115 related articles for article (PubMed ID: 2749491)

  • 21. Combined actions of 5-fluorouracil and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on human colonic carcinoma cells in vitro.
    Sutton JE; Roos IA; Hillcoat BL
    Cancer Res; 1982 Dec; 42(12):5172-5. PubMed ID: 7139620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I trial of combination methotrexate and methyl-CCNU in patients with advanced neoplastic diseases.
    Lehane DE; Lane M; Tranum B; Costanzi J; Padilla F
    Cancer Treat Rep; 1977 Aug; 61(5):889-91. PubMed ID: 329982
    [No Abstract]   [Full Text] [Related]  

  • 23. Methyl-CCNU (NSCU-95441) versus methyl-CCNU plus cyclophosphamide (NSC-26271) in advanced gastrointestinal cancer.
    Rossi A; Riva A; Bonadonna G
    Cancer Chemother Rep; 1975; 59(6):1161-2. PubMed ID: 769958
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of the agar diffusion chamber for the exposure of human tumor cells to drugs.
    Selby PJ; Steel GG
    Cancer Res; 1982 Nov; 42(11):4758-62. PubMed ID: 7127312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
    Diggs CH; Wiernik PH; Smyth AC
    Cancer Treat Rep; 1977 Nov; 61(8):1581-3. PubMed ID: 336200
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of vincristine, CCNU and methyl-CCNU at high level doses in an experimental murine renal adenocarcinoma model.
    Williams PD; Kantor P; Murphy GP
    Res Commun Chem Pathol Pharmacol; 1981 Mar; 31(3):529-36. PubMed ID: 7255884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iv methyl-CCNU, VM-26, and cranial irradiation in therapy for malignant brain tumors.
    Gutin PH; Walker MD
    Cancer Treat Rep; 1977 Dec; 61(9):1715-7. PubMed ID: 597821
    [No Abstract]   [Full Text] [Related]  

  • 28. Phase II study of methyl-CCNU in the treatment of advanced pancreatic carcinoma.
    Moertel CG; Douglass HO; Hanley J; Carbone PP
    Cancer Treat Rep; 1976 Nov; 60(11):1659-61. PubMed ID: 1035508
    [No Abstract]   [Full Text] [Related]  

  • 29. Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
    Wittes RE; Hong WK; Gatchell L; Krakoff IH; Golbey RB
    Oncology; 1977; 34(1):45-6. PubMed ID: 865760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
    Creagan ET; Ahmann DL; Schutt AJ; Green SJ
    Cancer Treat Rep; 1982 Jun; 66(6):1425-6. PubMed ID: 7083244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on drug resistance in a human melanoma xenograft system.
    Osieka R
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():85-98. PubMed ID: 6539651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response of human colon carcinoma xenografts to recombinant human tumor necrosis factor (TNF).
    Osieka R; Glatte P; Niederle N; Schmidt CG
    Strahlenther Onkol; 1989 Jul; 165(7):552-4. PubMed ID: 2749495
    [No Abstract]   [Full Text] [Related]  

  • 33. An inverse relationship between the growth rate of human melanoma xenografts and their response to some cytostatic drugs.
    Fodstad O; Aass N; Pihl A
    Br J Cancer; 1980 May; 41(5):829-31. PubMed ID: 7426308
    [No Abstract]   [Full Text] [Related]  

  • 34. Response of metastatic cloacogenic carcinoma to treatment with semustine.
    Zimm S; Wampler GL
    Cancer; 1981 Dec; 48(12):2575-6. PubMed ID: 7306917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.
    Micetich KC; Jensen-Akula M; Mandard JC; Fisher RI
    Am J Med; 1981 Dec; 71(6):967-72. PubMed ID: 7032289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
    Ahmann DL; Bisel HF; Edmonson JH; Hahn RG; Eagan RT; O'Connell MJ; Frytak S
    Clin Pharmacol Ther; 1976 Jun; 19(6):821-4. PubMed ID: 773589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased cytotoxicity of 1-(2-chloroethyl)-1-nitroso-3(4-methyl)-cyclohexylurea by pretreatment with O6-methylguanine in resistant but not in sensitive human melanoma cells.
    Dempke W; Nehls P; Wandl U; Soll D; Schmidt CG; Osieka R
    J Cancer Res Clin Oncol; 1987; 113(4):387-91. PubMed ID: 3597524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of solid tumors and lymphomas with methyl-CCNU (NSC-95441): a phase II study.
    Firat D; Tekuzman G
    Cancer Chemother Rep; 1975; 59(5):1021-3. PubMed ID: 1106843
    [No Abstract]   [Full Text] [Related]  

  • 39. Emergence of nitrosourea resistant sublines of Lewis lung tumour following MeCCNU treatment in vivo.
    Stephens TC; Adams K; Peacock JH
    Br J Cancer; 1986 Feb; 53(2):237-45. PubMed ID: 3954945
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
    Hill HZ; Hill GJ
    Cancer Res; 1982 Mar; 42(3):838-42. PubMed ID: 7059982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 56.